Summary
Global Markets Direct’s, ‘Diabetic Peripheral Neuropathy - Pipeline Review, H2 2016’, provides an overview of the Diabetic Peripheral Neuropathy pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Diabetic Peripheral Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Peripheral Neuropathy and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Diabetic Peripheral Neuropathy
- The report reviews pipeline therapeutics for Diabetic Peripheral Neuropathy by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Diabetic Peripheral Neuropathy therapeutics and enlists all their major and minor projects
- The report assesses Diabetic Peripheral Neuropathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Diabetic Peripheral Neuropathy
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Diabetic Peripheral Neuropathy
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Diabetic Peripheral Neuropathy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Achelios Therapeutics, Inc.
Celgene Corporation
Commence Bio, Inc.
Crescita Therapeutics Inc.
Glenmark Pharmaceuticals Ltd.
Relief Therapeutics S.A.
ViroMed Co., Ltd.
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Diabetic Peripheral Neuropathy Overview 7
Therapeutics Development 8
Pipeline Products for Diabetic Peripheral Neuropathy - Overview 8
Pipeline Products for Diabetic Peripheral Neuropathy - Comparative Analysis 9
Diabetic Peripheral Neuropathy - Therapeutics under Development by Companies 10
Diabetic Peripheral Neuropathy - Therapeutics under Investigation by Universities/Institutes 11
Diabetic Peripheral Neuropathy - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Diabetic Peripheral Neuropathy - Products under Development by Companies 15
Diabetic Peripheral Neuropathy - Products under Investigation by Universities/Institutes 16
Diabetic Peripheral Neuropathy - Companies Involved in Therapeutics Development 17
Achelios Therapeutics, Inc. 17
Celgene Corporation 18
Commence Bio, Inc. 19
Crescita Therapeutics Inc. 20
Glenmark Pharmaceuticals Ltd. 21
Relief Therapeutics S.A. 22
ViroMed Co., Ltd. 23
Diabetic Peripheral Neuropathy - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
atexakin alfa - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
benfotiamine - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
BNV-222 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
CMB-200 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
Flexicaine Peel - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
GRC-17536 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
ketoprofen - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
ND-07 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
PDA-002 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
pirenzepine hydrochloride - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Small Molecule for Pain - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
Small Molecules to Inhibit Hsp90 for Amyotrophic Lateral Sclerosis and Peripheral Neuropathy - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
U-2902 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
VM-202 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
Diabetic Peripheral Neuropathy - Dormant Projects 52
Diabetic Peripheral Neuropathy - Discontinued Products 53
Diabetic Peripheral Neuropathy - Product Development Milestones 54
Featured News & Press Releases 54
Jun 27, 2016: VM BioPharma Announces First Patient Dosed in Phase 3 Study of Gene Therapy Candidate, VM202, in Painful Diabetic Peripheral Neuropathy 54
Mar 06, 2015: ViroMed dba VM BioPharma: A Phase II Study Done at Northwestern Hospital Shows Potential Relief for Diabetics with Painful Condition 54
Appendix 57
Methodology 57
Coverage 57
Secondary Research 57
Primary Research 57
Expert Panel Validation 57
Contact Us 57
Disclaimer 58
List of Tables
Number of Products under Development for Diabetic Peripheral Neuropathy, H2 2016 8
Number of Products under Development for Diabetic Peripheral Neuropathy - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Number of Products under Investigation by Universities/Institutes, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Clinical Stage Development, H2 2016 13
Comparative Analysis by Early Stage Development, H2 2016 14
Products under Development by Companies, H2 2016 15
Products under Investigation by Universities/Institutes, H2 2016 16
Diabetic Peripheral Neuropathy - Pipeline by Achelios Therapeutics, Inc., H2 2016 17
Diabetic Peripheral Neuropathy - Pipeline by Celgene Corporation, H2 2016 18
Diabetic Peripheral Neuropathy - Pipeline by Commence Bio, Inc., H2 2016 19
Diabetic Peripheral Neuropathy - Pipeline by Crescita Therapeutics Inc., H2 2016 20
Diabetic Peripheral Neuropathy - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2016 21
Diabetic Peripheral Neuropathy - Pipeline by Relief Therapeutics S.A., H2 2016 22
Diabetic Peripheral Neuropathy - Pipeline by ViroMed Co., Ltd., H2 2016 23
Assessment by Monotherapy Products, H2 2016 24
Number of Products by Stage and Target, H2 2016 26
Number of Products by Stage and Mechanism of Action, H2 2016 28
Number of Products by Stage and Route of Administration, H2 2016 30
Number of Products by Stage and Molecule Type, H2 2016 32
Diabetic Peripheral Neuropathy - Dormant Projects, H2 2016 52
Diabetic Peripheral Neuropathy - Discontinued Products, H2 2016 53
List of Figures
Number of Products under Development for Diabetic Peripheral Neuropathy, H2 2016 8
Number of Products under Development for Diabetic Peripheral Neuropathy - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Comparative Analysis by Clinical Stage Development, H2 2016 13
Comparative Analysis by Early Stage Products, H2 2016 14
Assessment by Monotherapy Products, H2 2016 24
Number of Products by Top 10 Targets, H2 2016 25
Number of Products by Stage and Top 10 Targets, H2 2016 25
Number of Products by Top 10 Mechanism of Actions, H2 2016 27
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 27
Number of Products by Routes of Administration, H2 2016 29
Number of Products by Stage and Routes of Administration, H2 2016 29
Number of Products by Molecule Types, H2 2016 31
Number of Products by Stage and Molecule Types, H2 2016 31
